Table 2.
Associations of α‐SMA and CD66b coexpression with clinicopathologic characteristics in patients with gastric cancer
| Characteristics | α‐SMA+CAFs & CD66b+TANs, n (%) | P value | |||
|---|---|---|---|---|---|
| α‐SMAlowCD66blow | α‐SMAlowCD66bhigh | α‐SMAhighCD66blow | α‐SMAhighCD66bhigh | ||
| All cases | 83 (38.6) | 39 (18.1) | 29 (13.5) | 64 (29.8) | |
| Sex | .265 | ||||
| Female | 23 (39.0) | 6 (10.2) | 9 (15.3) | 21 (35.6) | |
| Male | 60 (38.5) | 33 (21.2) | 20 (12.8) | 43 (27.6) | |
| Age (years) | .953 | ||||
| <60 | 38 (36.9) | 20 (19.4) | 14 (13.6) | 31 (30.1) | |
| ≥60 | 45 (40.2) | 19 (17.0) | 15 (13.4) | 33 (29.5) | |
| Tumor size (cm) | .237 | ||||
| <5 | 38 (46.9) | 14 (17.3) | 10 (12.3) | 19 (23.5) | |
| ≥5 | 45 (33.6) | 25 (18.7) | 19 (14.2) | 45 (33.6) | |
| Differentiation | .540 | ||||
| Well/moderate | 15 (31.9) | 9 (19.1) | 9 (19.1) | 14 (29.8) | |
| Poor | 68 (40.5) | 30 (17.9) | 20 (11.9) | 50 (29.8) | |
| Location | .353 | ||||
| Upper | 12 (34.3) | 3 (8.6) | 4 (11.4) | 16 (45.7) | |
| Middle | 16 (35.6) | 9 (20.0) | 6 (13.3) | 14 (31.1) | |
| Lower | 55 (40.7) | 27 (20.0) | 19 (14.1) | 34 (25.2) | |
| pTNM stage | .021 | ||||
| I | 18 (56.3) | 8 (25.0) | 1 (3.1) | 5 (15.6) | |
| II | 16 (33.3) | 7 (14.6) | 12 (25.0) | 13 (27.1) | |
| III | 49 (36.3) | 24 (17.8) | 16 (11.9) | 46 (34.1) | |
| Adjuvant chemotherapy | .496 | ||||
| Yes | 39 (36.1) | 21 (19.4) | 12 (11.1) | 36 (33.3) | |
| No | 44 (41.1) | 18 (16.8) | 17 (15.9) | 28 (26.2) | |
Abbreviations: α‐SMA, α‐smooth muscle actin; CAFs, cancer‐associated fibroblasts; TANs, tumor‐associated neutrophils.
P < .05 is considered statistically significant (bold).